INTRODUCTION
I nrecentyears,thedevelopmentofvascularendothelial growthfactor(VEGF)inhibitorsthatcanbeintravitreally injectedhasrevolutionizedthetherapeuticapproachfor neovascularage-relatedmaculardegeneration(AMD). Tightlycontrolledmulticenterrandomizedcontrolledstudies haveconvincinglyshownthetreatmentbenefitsfor neovascularAMDpatientswithranibizumab(Lucentis, Genetech,SanFrancisco,California,USA),bevacizumab (Avastin,Genetech,SanFrancisco,California,USA)and aflibercept(Eylea,BayerHealthcarePharmaceuticals,Berlin, Germany) [1] [2] [3] [4] [5] .RanibizumabislicensedforAMDsince2007 andafliberceptin2012.Bothdrugsareapprovedbythe NationalInstituteforHealthandClinicalExcellencein UnitedKingdomandtheHospitalAuthorityinHongKong, whereasbevacizumabisnot.Giventhesubstantialhigher costsofranibizumabandaflibercept,manyprivatepatients stillprefer off-labeluseofbevacizumabforAMD. Nevertheless,inclinicaltrials,rigidtreatmentandfollow-up protocolsareusuallymandatedandpatientsarerecruited accordingtostrictinclusionandexclusioncriteriatoensure validityofresults.Furthermore,aheavytreatmentburdenon allpartiesinvolvedinroutineclinicalpracticehasledto dosingregimensthatarelessintensivethanthoseusedin clinicaltrials,suchasthePrONTOandtreat-and-extend regimens [6] [7] .Itisuncertainwhetheridenticaloutcomesfrom clinicaltrialswillbereplicatedinthewidercommunityin everydaypractice.Here,wedescribethesafetyandefficacy ofintravitrealbevacizumab(IVB)over12-24mo of non-investigationaltreatmentinanon-selectedpopulationof neovascularAMDpatients. SUBJECTSANDMETHODS [3] [4] .Thestudywasperformedwithoutfinancial supportfromthepharmaceuticalindustry,ararityfor prospectivetrialsofthissize.At12mo,bevacizumab administeredmonthlywasequivalenttoranibizumab administeredmonthly,with8.0and8.5ETDRSletters gained,respectively.Bevacizumabadministeredasneeded wasequivalenttoranibizumabasneeded,with5.9and6.8 ETDRSlettersgainedrespectively [3] .Ourstudyobtaineda meangainof4.76lettersat12mo.Theproportionofpatients whogained>15letterswas33.3%,whichwassimilartothe resultsfromrandomizedcontroltrials(RCTs) (Table2). However,theproportionofpatientswhodidnothavea decreaseinvisualacuityof15lettersormorefrombaseline wasslightlylower(90.1%)inourserieswhencomparedwith thecohortsinclinicaltrials(Table2).SimilartotheCATT study,mostofthechangeinmeanvisualacuityoccurred duringthefirstyear,withrelativelittlechangeduringthe secondyear [4] .Nonetheless,forpatientsthatcompleted24mo offollow-upinthisstudy,27.3%ofeyesgained>15letters and81.8%lost<15letters. Oneofthepotentialreasonsforlessoptimalvisualoutcome inourstudycomparedwithclinicaltrialsisthelowermean numberofinjections(4.6 7.7inCATTyear1,and9.2 14.1inCATTyear2).Suchdiscrepancyinvisualoutcomeof IVBtreatmentinroutineclinicalpracticewasattributedto poorercompliancetotreatmentprotocol,longertime intervalsbetweenfollow-upvisits,lessnumberoffollow-up OCTsperformedandfewerreinjections [10] [11] [12] [13] [14] [15] [16] .TheSwedish LucentisQualityRegistryfoundagoodimprovementin visualacuityafter3injectionsofranibizumab,butthis subsequentlydroppedbacktopretreatmentlevels [13] .Similar resultswerefoundbytheWAVEstudyinGermanyandin theFrenchLumierestudy [10, [14] [15] . Nonetheless,ina multi-centerprospectiveauditof12mo outcomesof anti-VEGFfor1140treatment-na觙veAMDpatientsin Australiathatreceivedahighermeannumberofinjections(7 injections)thanpreviousobservationalstudies,thereported improvementwas4.7logMARletters,whichwasstill somewhatlessthanthevisualgaininphase3clinicaltrials [16] . Besidesthenumberofinjections,caseselection,methodsin visualacuitymeasurement [usingSnellencharts,early treatmentdiabeticretinopathystudy(ETDRS)chartsor electronicvisual-acuitytests],OCTparametersinmonitoring diseaseactivityandtreatmentregimensalsocontributedto thedifferencesinvisualoutcomesinobservationalstudies comparedwithclinicaltrials. Ourstudyobservedthatthegreatestincreaseinvisualacuity inthesubgroupofpatientswithbaselinevisualacuity <20/320andpatientswithpoorervisualacuitywerenot recruitedinclinicaltrials.Furthermore,ourstudyrevealed thattheonlystatisticallysignificantcovariatethatinfluenced visualoutcomeidentifiedbyregressionanalysisinourstudy wasbaselineBCVA.TheMARINAandANCHORsubgroup analysesrecognizedthatthemostimportantpredictorsof visualacuityoutcomeswerebaselinevisualacuity,followed byCNVlesionsizeandage [17] [18] .Itimpliedthatpatientswith lowerbaselinevisualacuityprobablyhadagreaterchance forimprovementfrombaselineovertime(ceilingeffect),and viceversa(flooreffect)forthosewithhigherbaselinevisual acuity(flooreffect).Baselinepredictorsfor1yvisual outcomeidentifiedinCATTstudywereage,CNVlesion size,andelevationofretinalpigmentepithelium [19] .These [20] alsoreportedthat bevacizumabwaseffectiveinimprovingvisualacuity withoutastatisticallysignificantdifferencebetweenthetwo groups.Jyothi [21] reported2casesofRPEripatthe extrafovealedgeoffibroticlesionafteranti-VEGFinjections intheirseriesof25priorPDT-treatedeyes.Noneofthe subjectshadincreasedRPEatrophyandthemajorityhad improvedorstabilizedvision(lossof<15ETDRSletters)at 6mo.PatientswhohadpriorPDTinourseriesrequired significantlymoremeannumberofinjectionsperyearthan treatmentnaivepatientsat12mo,possiblybecausethese patientsweremorepronetorecurrenceorpersistenceof CNV.Intheory,priorPDTmayincreaseretinaland subretinalfibrosisandinducechoriocapillaryatrophywhich couldlimitthepotentialvisualrecoveryofpatientssubjected toanti-VEGF [22] .Nevertheless,inclinicalpractice,patients whohadreactivatedorpersistentCNVafterPDTcouldstill benefitfromIVBbecausethetwotherapiesmayhave differentmechanismsintreatingneovascularAMD [23] . Nosignificantvisionthreateningocularsideeffects,suchas endophthalmitisandretinaldetachment,occurredinthis seriesduringtheentireperiodoffollow-up.Nonetheless,the samplesizeinourseriesmaybetoosmalltodetectocular adverseeventsfollowingIVB.McCannel [24] reportedthe incidenceofendophthalmitiswas0.049%(approximately1 of1949injections)inameta-analysisof105531injections fromallmajorU.S.-basedstudiesfrom2005-2010.Arevalo [25] reportednosystemicadverseeventsinthegroupof neovascularAMDpatientsthatreceived1.25mg,butforthe groupthatreceived2.50mg,theincidencesofsystemic adverseeventswashigher(2.6%hadarterialhypertension and1.3%hadstroke).Nosystemicadverseeventoccurredin ourseriesinwhichthemajorityreceived1.25mg bevacizumabandonly5patientsreceived2.50mg. Therewerenodifferencesinendophthalmitisratesor mortalitybetweentreatmentgroupsintheCATTstudy, however,morepatientsthatreceivedbevacizumabhad multiplesystemicseriousadverseeventsthanthosereceiving ranibizumab,24% 19%at1yand40% 32%at2y [3] [4] .
Thestudywasperformedinaccordancewiththestandardsof theDeclarationofHelsinkiandwasapprovedbythe InstitutionalReviewBoardoftheHongKongSanatorium
Nonetheless,theseadverseeventsweredistributedacrossa widerangeoforganclass,andmanyseemedunrelatedto VEGFsuppression.Theseadverseeventsincludedinfections, palpitationsandaccidents.IntheinhibitionofVEGFin age-relatedchoroidalneovascularization(IVAN)trial,a United Kingdom-basedstudyinvolving610 patients comparingbevacizumabwithranibizumab,giveneither monthlyorasneeded,thereweremorearteriothrombotic eventsandheartfailurewithranibizumab [26] [27] .Ithasbeen arguedthatsamplesizesofCATTandIVANtrialswere insufficientlypoweredtoidentifydifferencesindrug-related adverseevents.Thevariableratesofadverseeventsamongst studiedsubjects,andevenamongstcontrols,maysuggest typeIerror [28] . Thehypothesisthatthegreaterbindingaffinityofaflibercept mayequatetoaclinicallyhigherefficacyand/orlonger durationofactioncomparedtoranibizumabwastestedin twophase-IIInon-inferioritystudies,VIEW1andVIEW2 [5] . Itwasdemonstratedthatbothafliberceptmonthlyand aflibercepteverytwomonthsafterthreeinitialmonthlydoses groupswerenon-inferiortomonthlyranibizumabintermsof theamountofvisiongained.Clinically,thismaygive patientsandphysiciansanothertherapeuticoptionthat involvesinjectioneverytwomonthsafterthreeloading monthlydoses,whichcouldreducetheriskassociatedwith regularintravitrealinjectionsandthetreatmentburdento patients.Inatrade-offanalysisofefficacyandadverseevents ofaflibercept,ranibizumabandbevacizumabinAMD patients,bevacizumabhassomedisadvantagesinsevereside effectscomparedwiththeothertwolicenseddrugs,whereas theefficacyandsideeffectprofilesofranibizumaband afliberceptwereverysimilar [29] . Althoughmanyfactorsdeterminethechoiceofanti-VEGF drugsforthetreatmentofAMD,theirsignificantdifference incosthasbeenanimportantfactor.Thesingle-dosecostof aflibercept(US$1850)iscomparabletoranibizumab(US $1950),butstillsubstantiallymorethanbevacizumab (approximatelyUS$50) [29] [30] [31] [32] .Sincethesingle-dosecostsand efficaciesofthetwodrugsarecomparable,physicians'useof afliberceptinsteadofranibizumabmaylargelydependupon theirperceptionsofthedrugs'durability.Thecostoftreating patientswithaflibercept2mgevery8wk maybe approximatelyhalfthatwithranibizumab.Cost-conscious physicians,however,willalsobeforcedtoconsiderthe relativemeritsofmoreexpensive,lessfrequentdosingwith afliberceptversusthemorefrequentlydosed,lowercost alternative,off-labelbevacizumab.Giventherisingdemands forhealthcareandlimitedbudgets,localevidenceon incrementalcostandcost-effectivenessisofparticular importanceindecidingthetreatmentofchoiceinAMD patients. [33] [34] . Thereweretwodifferentdosagesofbevacizumabinthis study.Consideringthefactthatranibizumabhasamolecular weightapproximatelyonethirdofbevacizumab,thedoseof bevacizumabcontainingthesamenumberofmolecules wouldbeapproximately1.25mg [35] .Somephysicians believedthatincreasingthedosageto2.50mgcouldimprove itsefficacy.However,ahead-to-headtrialrevealedno differenceineffectbetweenthetwodosages [35] . Thesignificanceofdatafromobservationalstudiesisthat theyprovideanindicationofwhatishappeninginroutine clinicalpractice,incontrasttoresultsoftightlycontrolled clinicaltrials,whichmayormaynotbeachievableinroutine practice.Ourstudycanbeusefulinprovidingpatients' expectationsforvisualstabilizationorimprovementafter receivingless-than-monthlyIVB,whichmaybeamore preferabletreatmentregimenespeciallywhencostisa concern. Morefrequentfollow-upvisitsand OCT assessmentsofdiseaseactivitymayoptimizeefficacyin clinicalpractice.Furthermore,ourstudyhadrevealedthat bevacizumabmaybesafeandefficaciousinneovascular AMDpatientswhoreceivedpriorPDTandinthosewith baselineBCVA<20/320,whilenoevidencehadbeen providedbyRCTsonthesesubgroups.
